MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
11.53
-0.18
-1.54%
After Hours: 11.76 +0.23 +1.99% 18:09 12/18 EST
OPEN
11.93
PREV CLOSE
11.71
HIGH
11.93
LOW
11.50
VOLUME
7.89K
TURNOVER
--
52 WEEK HIGH
76.00
52 WEEK LOW
4.560
MARKET CAP
54.12M
P/E (TTM)
-3.8001
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INKT last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at INKT last week (1201-1205)?
Weekly Report · 12/08 09:40
Weekly Report: what happened at INKT last week (1124-1128)?
Weekly Report · 12/01 09:38
Weekly Report: what happened at INKT last week (1117-1121)?
Weekly Report · 11/24 09:41
MiNK Therapeutics announces publication of new preclinical data for MiNK-215
TipRanks · 11/20 16:45
MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors
Reuters · 11/20 16:42
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
Barchart · 11/20 10:42
Weekly Report: what happened at INKT last week (1110-1114)?
Weekly Report · 11/17 09:41
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.